Omvoh (Mirikizumab-mrkz)
- Drug Name: Omvoh
- Generic Name: Mirikizumab-mrkz
- Manufactured By: Eli Lilly and Company.
Medical uses
Warning & Precautions
Documentation & Availability
Sourcing & Delivery
FAQ
Medical uses
The adult treatment for moderately to severely active ulcerative colitis is OMVOH, an interleukin-23 antagonist.
Recommended Dosage:
Before Starting Treatment:
- Check for tuberculosis (TB) infection.
- Get liver enzyme and bilirubin levels checked.
- Ensure all vaccinations are up to date.
Dosage Forms and Strengths:
Intravenous Infusion (IV):
- This is a solution for injection, meaning it can be introduced directly into the bloodstream.
- Each vial contains 300 mg of the solution, and it’s conveniently measured at 20 mg per milliliter (20 mg/mL).
- This involves injecting the solution just beneath the skin.
- The prefilled pen makes it simple to use, containing a solution with a concentration of 100 mg per milliliter (100 mg/mL).
- Induction Phase: Receive 300 mg through an IV drip over 30 minutes at Weeks 0, 4, and 8.
- Maintenance Phase: Take 200 mg via subcutaneous injection (two 100 mg injections) at Week 12, then every 4 weeks.
Detailed instructions on preparing, administering, and storing the medication can be found in the complete prescribing information.
Warning & Precautions
- Hypersensitivity Reactions: Hypersensitivity reactions to OMVOH can manifest as severe allergic responses, including anaphylaxis and issues related to the infusion process. Patients are advised to be vigilant for any signs of a severe allergic reaction. If such a reaction occurs, it is imperative to discontinue OMVOH immediately and seek prompt medical attention. Timely intervention is crucial in managing hypersensitivity reactions effectively.
- Infections:The use of OMVOH may increase the susceptibility to infections. It is strongly recommended not to initiate treatment if a patient is currently experiencing a significant ongoing infection. In the event of a serious infection developing during the course of OMVOH treatment, it is advised to withhold further administration until the infection is fully resolved. This precaution aims to ensure the patient’s overall well-being and prevent complications.
- Tuberculosis: Individuals with active tuberculosis (TB) are not suitable candidates for OMVOH treatment. Continuous monitoring for signs of TB is essential both during and after the OMVOH treatment period. If any indications of TB arise, appropriate diagnostic measures and interventions should be promptly undertaken. This precautionary measure helps in addressing the specific risks associated with TB in individuals undergoing OMVOH therapy.
- Hepatotoxicity (Liver Issues): Cases of drug-induced liver injury have been reported in association with OMVOH. Regular monitoring of liver enzymes and bilirubin levels is recommended at the initiation of treatment and for at least 24 weeks into the therapy. Should concerns about potential liver injury arise, it is advisable to temporarily suspend OMVOH treatment until a thorough evaluation rules out liver-related issues. This cautious approach ensures patient safety and allows for timely intervention if needed.
- Immunizations: During the course of OMVOH treatment, it is crucial to avoid receiving live vaccines. Live vaccines pose potential risks during immunosuppressive therapy, and their administration may compromise the patient’s well-being. This precautionary measure aligns with best practices in managing patients undergoing OMVOH treatment, emphasizing the importance of preserving immune function and minimizing potential complications related to live vaccines.
Documentation & Availability
If you are considering the import of Omvoh (Mirikizumab-mrkz) to India, please be aware that Omvoh can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified medical practitioner.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
Order Confirmation Process:
The order for Omvoh will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Availability of Omvoh in India:
Omvoh (Mirikizumab-mrkz) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Omvoh can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Omvoh (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.
For inquiries regarding the price of Omvoh in India and to initiate the ordering process, please reach out to us through the following contact details:
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Sourcing & Delivery
Indian Pharma Network is proficient in sourcing Omvoh from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
FAQ
What is Omvoh, and what conditions does it treat?
Omvoh is a medication containing Mirikizumab-mrkz, an interleukin-23 antagonist. It is prescribed for the treatment of moderately to severely active ulcerative colitis in adults.
How is Omvoh administered, and what are the recommended dosages?
Omvoh is administered through intravenous infusion and subcutaneous injection. The induction phase involves receiving 300 mg through intravenous infusion at Weeks 0, 4, and 8. The maintenance phase requires a 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
What precautions should be taken while using Omvoh?
Patients should be evaluated for tuberculosis (TB) infection before starting treatment. Liver enzymes and bilirubin levels should be monitored, and all age-appropriate vaccinations should be completed. Hypersensitivity reactions, infections, tuberculosis, and hepatotoxicity are potential concerns, and live vaccines should be avoided during treatment.
How can Omvoh be imported globally, and what documentation is required?
For global import, patients or government hospitals need a valid prescription, diagnostic reports, and government-issued identification. Indian Pharma Network (IPN) facilitates the import process, ensuring compliance with legal requirements.
How can individuals inquire about the availability and price of Omvoh in India and initiate the ordering process?
To inquire about Omvoh’s availability and pricing in India, individuals can contact Indian Pharma Network through phone (+91-9310090915), toll-free number (1800-889-1064), or email (info@indianpharmanetwork.in). IPN is dedicated to meeting healthcare needs by providing quality medications with timely delivery.
For specific medical concerns and detailed information, consulting with a healthcare professional is recommended.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.